AstraZeneca PLC (AZN) Revenue
The annual revenue for AstraZeneca PLC (AZN) is $60.44 Billion with a year-over-year growth of +9.93%. Revenue represents the total income generated from the company's primary business operations.
Annual Revenue (TTM)
$60.44B
$60.44 Billion
Year-over-Year Growth
+9.93%
vs. $54.07B prior year
Revenue CAGR
+16.99%
5 Year compound annual growth rate
Revenue CAGR (Compound Annual Growth Rate)
1 Year
+9.93%
3 Year
+11.29%
5 Year
+16.99%
10 Year
+9.33%
15 Year
+4.12%
20 Year
+4.64%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Revenue History
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $58.74B | +$4.67B | +8.63% |
| 2024 | $54.07B | +$8.26B | +18.03% |
| 2023 | $45.81B | +$1.46B | +3.29% |
| 2022 | $44.35B | +$6.93B | +18.53% |
| 2021 | $37.42B | +$10.80B | +40.58% |
| 2020 | $26.62B | +$2.23B | +9.16% |
| 2019 | $24.38B | +$2.29B | +10.38% |
| 2018 | $22.09B | ($375.00M) | (1.67%) |
| 2017 | $22.46B | ($537.00M) | (2.33%) |
| 2016 | $23.00B | ($1.71B) | (6.90%) |
Revenue Growth Summary
TTM Growth
+9.93%
3-Year Avg Growth
+11.29%
5-Year Avg Growth
+16.99%
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot